Cost-effectiveness of Argatroban Versus Heparin Anticoagulation in Adult Extracorporeal Membrane Oxygenation Patients.

Autor:	Cho AE; WellStar Kennestone Hospital, Marietta, GA, USA., Jerguson K; WellStar Kennestone Hospital, Marietta, GA, USA., Peterson J; WellStar Kennestone Hospital, Marietta, GA, USA., Patel DV; WellStar Kennestone Hospital, Marietta, GA, USA., Saberi AA; WellStar Kennestone Hospital, Marietta, GA, USA.
Jazyk:	angličtina
Zdroj:	Hospital pharmacy [Hosp Pharm] 2021 Aug; Vol. 56 (4), pp. 276-281. Date of Electronic Publication: 2019 Dec 13.
DOI:	10.1177/0018578719890091
Abstrakt:	Purpose: The purpose of this study was to evaluate the cost effectiveness of argatroban compared to heparin during extracorporeal membrane oxygenation (ECMO) therapy. Methods: This was a retrospective study of patients who received argatroban or heparin infusions with ECMO therapy at a community hospital between January 1, 2017 and June 30, 2018. Adult patients who received heparin or argatroban for at least 48 hours while on venovenous (VV) or venoarterial (VA) ECMO were included. Patients with temporary mechanical circulatory assist devices were excluded. Each continuous course of anticoagulant exposure that met the inclusion criteria was evaluated. The primary endpoint was the total cost of anticoagulant therapy for heparin versus argatroban, including all administered study drugs, blood or factor products, and associated laboratory tests. Secondary endpoints included safety and efficacy of anticoagulation with each agent during ECMO. Documentation of bleeding events, circuit clotting, and ischemic events were noted. Partial thromboplastin time (PTT) values were evaluated for time to therapeutic range and percentage of therapeutic PTTs. Results: A total of 11 courses of argatroban and 24 courses of heparin anticoagulation were included in the study. The average cost per course of argatroban was less than the average cost per course of heparin ($7,091.98 vs $15,323.49, respectively; P value = 0.15). Furthermore, argatroban was not associated with an increased incidence of bleeding, thrombotic, or ischemic events. Conclusion: Argatroban may be more cost-effective during ECMO therapy in patients with low antithrombin III levels without increased risk of adverse events. Competing Interests: Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. (© The Author(s) 2019.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu